| |
| |
Gene Symbol |
CD163 |
| |
Aliases |
M130, MM130, SCARI1 |
| |
Entrez Gene ID |
|
| |
Gene Name |
CD163 molecule |
| |
Chromosomal Location |
12p13.31 |
| |
HGNC ID |
|
| |
Summary |
The protein encoded by this gene is a member of the scavenger receptor cysteine-rich (SRCR) superfamily, and is exclusively expressed in monocytes and macrophages. It functions as an acute phase-regulated receptor involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages, and may thereby protect tissues from free hemoglobin-mediated oxidative damage. This protein may also function as an innate immune sensor for bacteria and inducer of local inflammation. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2011]
|
| |
RefSeq DNA |
|
| |
RefSeq mRNA |
|
| |
e!Ensembl
|
| Protein Information |
| |
Protein Name |
Scavenger receptor cysteine-rich type 1 protein M130, hemoglobin scavenger receptor, macrophage-associated antigen |
| |
Function |
|
Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.; After shedding, the soluble form (sCD163) may play an anti-inflammatory role, and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions |
|
| |
|
|
| |
UniProt |
|
| |
Pfam |
| Pfam Accession |
Pfam ID |
| PF00530 |
SRCR |
|
|
|
|
|
|
Interactions |
| | |
| STRING |
MINT |
IntAct |
| ENSP00000360541 |
P23786 |
P23786 |
|
| | |
View interactions
|
| |
| |
Associated Diseases
| Disease group | Disease Name | References |
| Endocrine System Diseases |
| PCOS |
|
| Immune System Diseases |
| Glomerulonephritis |
|
| Neoplasms |
| Carotid Atherosclerosis |
|
| Nervous System Diseases |
| Carotid Artery Diseases |
|
| Moyamoya disease |
|
| Psychiatric/Brain disorders |
| Schizophrenia |
|
|
|
References |
| |
| |
| Oruc A S, Yilmaz N, Inal H A, Gorkem U, Gulsen P, Ugur M, Buyukkagnici U |
| Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey.| Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey.| Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey.| Department of Obstetrics and Gynecology, Hitit University, Corum, Turkey.| Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey.| Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey.| Zekai Tahir Burak Women's Health Education and Research Hospital, Department of Biochemistry, Ankara, Turkey. |
| Horm Metab Res. 2016 Jun;48(6):399-403. doi: 10.1055/s-0042-101028. Epub 2016 Mar |
Abstract
The aim of this study was to determine serum soluble CD163 levels in patients with polycystic ovary syndrome and its relation to clinical and metabolic parameters. Eighty-four women aged 18-45 years, 43 with polycystic ovary syndrome and 41 controls were recruited in this case-control study. Serum sCD163 levels of the groups were compared. Other metabolic, hormonal, and clinical parameters including, body mass index, HOMA-IR, highly sensitive C- reactive protein, glucose, glycated hemoglobin, lipids, luteinizing hormone, and total testosterone and waist/hip circumference were also investigated. Patients were further subgrouped according to body mass index and sCD163 levels were investigated in obese and normal weight subjects. We performed a multiple regression analysis to investigate the independent predictors affecting soluble CD163 levels. Significantly higher soluble CD163 levels were found in patients with polycystic ovary syndrome (2.11+/-0.65 ng/ml vs. 1.69+/-0.85 ng/ml, p=0.012). We detected positive correlations of sCD163 with total testosterone, total cholesterol, and luteinizing hormone (r=0.330, p=0.002, r=0.356, p<0.001 and r=0.239, p=0.030, respectively). In the multiple linear regression analysis, total testosterone was the variable associated with the elevation of serum soluble CD163 levels. Soluble CD163, which is identified as a marker of inflammation and type II diabetes, is elevated in polycystic ovary syndrome. Elevated sCD163 levels were found to be associated with total testosterone. Further studies to elucidate the exact mechanism underlying the elevation of serum soluble CD163 in polycystic ovary syndrome are needed. |
|
|
|
| |
| © 2019, Biomedical Informatics Centre, NIRRH |
National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai-400 012
Tel: 91-22-24192104, Fax No: 91-22-24139412
|
